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Fourteen phenylacyl and 2-hydroxyphenylacyl azoles and their oxime derivatives of which 
three were new, 2-(2-methyl-1H-imidazol-1-yl)-1-phenylethanone oxime 7; 1-(2-
hydroxyphenyl)-2-(2-methyl-1H-imidazol-1-yl)ethanone oxime 13 and 1-(2-hydroxyphenyl)-
2-(1H-1,2,4 traizol-1-yl)ethanone oxime 14.  The yields obtained for the ketone derivatives 
were between 50 and 60%, and between 80 and 95% for the oxime derivatives. All 
compounds were characterized using NMR, IR, UV and GCMS, and were tested for their 
antifungal and antibacterial activity.  These compounds possessed moderate antifungal and 
weak antibacterial activity, with compound 12, 1-(2-hydroxyphenyl)-2-(1H-imidazol-1-
yl)ethanone oxime showing the highest antifungal activity with a MIC value of 1 µg mL-1.  In 
general, the 2'-hydroxy substituted compounds were shown to have better antifungal and 























































































































































































































1H NMR  proton nuclear magnetic resonance spectroscopy 
13C NMR  C-13 nuclear magnetic resonance spectroscopy 
CDCl3  deuterated chloroform 
COSY  correlated spectroscopy 
DMSO-d6 deuterated dimethyl sulfoxide 
DCM  Dichloromethane 
EIMS   electron impact mass spectroscopy 
EtOH  ethanol 
HMBC heteronuclear multiple bond coherence 
HREIMS high resolution electron impact mass spectroscopy 
HSQC  heteronuclear single quantum coherence 
MeOH  methanol 
MIC  minimum inhibitory concentration 
NOESY nuclear overhauser effect spectroscopy 
TLC  thin layer chromatography 
UV  ultraviolet 
d  doublet 
dd  double doublet 
Hz  hertz 
IR  infrared 








m  multiplet 
Rf  Retention factor 
s  singlet 
t  triplet 
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Chapter 1. Introduction 
The search for new compounds that could have useful practical applications is an ongoing 
process.  Compounds containing an azole ring possess properties which make them valuable 
in medicinal applications. Azoles are five-membered heterocyclic rings which contain 
nitrogen and at least one other heteroatom (Figure 1-1).  They are known to have a wide 
range of applications, such as antimicrobial, antitumor, anti-tubercular, and most commonly, 
antifungal activities.  We intend to evaluate the antifungal activity of compounds containing a 
phenyl ethanone backbone bonded to five membered heterocycles such as those below 











1H-imidazole 1H -1,2,4-triazole 2-methyl-1H -imidazole  
Figure 1-1   Structure of azole rings, imidazole, triazole and 2-methylimidazole 
 
Most antifungal drugs are highly toxic, and ineffective against new or re-emerging fungi due 
to the appearance of resistant strains.  In spite of ongoing research on antifungal agents, 
azoles are still the drug of choice against invasive fungal infections.  This is due to their low 
toxicity, fungistatic, and broad-spectrum properties (Aher et al., 2009).  The discovery of new 








There is a vast amount of literature reported on the synthesis of structurally modified 
analogues of azoles. In this study we have chosen to focus our attention on phenylacyl and 
hydroxyphenylacyl azoles and their oxime compounds (Figure 1-2).  Emami and co-workers 
(2008) developed an efficient protocol for the synthesis of 2-hydroxyphenylacyl azoles and 
its oxime derivative, where the azole and azolium compounds synthesized showed significant 
inhibition of fungal growth in vitro when compared to the reference drug fluconazole.  The 
study also indicated that the hydroxyl group and 4'- substitution on the phenyl ring increased 
the antifungal activity of the compound.  This was also shown by Chai et al. (2011), where 
they used molecular docking to show that substitution at the 2' and 4' positions on phenylacyl 
azoles form hydrophobic and van der Waals interactions with hydrophobic regions on 
lanesterol.  These substitutions increase the binding of these phenylacyl azole compounds to 
the active site; as shown by their antifungal activity at concentrations less than 1µg mL-1 
(Chai et al., 2011).  Therefore, 2-hydroxyphenylacyl azoles may be considered as promising 








Az: 1H-imidazole, 1H-1,2,4-triazole, 2-methyl-1H-imidazole  








1.1  Azole antifungals  
Fungi are eukaryotic microorganisms such as yeast and molds.  Many fungi have pathogenic 
potential and pose a continuous threat to human health and life. Healthy individuals are 
susceptible to a host of superficial mycoses (mycoses of skin, nails and hair), as well as 
severe life-threatening diseases such as histoplasmosis (Pfaller and Diekema, 2010; 
Kathiravan et al., 2012).  Invasive fungal infections are a significant cause of morbidity and 
mortality in individuals with increased vulnerability.  These are patients receiving 
immunosuppressive therapy, organ transplant patients and those infected with the human 
immunodeficiency virus (HIV) (Ranganathan, 2012).  
The development of polyene antifungals was the first major milestone in medical mycology 
and Amphotericin B quickly became the ‘Gold standard’ treatment for serious infections.  
Due to its numerous side effects and high toxicity a continued search for new drugs led to the 
discovery of azoles as potent antifungals (Maertens, 2004). 
These azoles were first reported to show antifungal activity by Woolley in 1944.  Interest in 
the antifungal activity of azole compounds only began to increase in the late 1960’s with the 
discovery of miconazole, econazole and ketoconazole, by Janssen pharmaceutica (Beerse, 
Belgium) (Maertens, 2004).  It wasn’t until the late 1980’s that the most useful alternative 









The most active antifungals contain an imidazole or triazole ring, which share the same 
mechanism of action.  The imidazoles are used to treat superficial mycoses, whereas the 
triazoles are more active in treating both superficial and systemic invasive fungal infections 








































Figure 1-3  Structures of some antifungal agents 
 
1.1.1  Mechanism of Action 
The mode of action of all azole antifungals is to inhibit the synthesis of ergosterol from 
lanosterol in fungal cell membranes.  Ergosterol is an essential component of fungal cell 
membranes, regulating its fluidity, asymmetry and integrity.  Azoles target the 14α-







a decrease in ergosterol and an accumulation of methyl steroids leading to the inhibition of 
fungal growth and replication (Maertens, 2004; Lass-Flörl, 2011; Kathiravan et al., 2012).  
Different targets for antifungal drugs are shown in Figure 1-4 (Kathiravan et al. 2012). 
 
Figure 1-4  Target sites for different antifungal drugs (Kathiravan et al., 2012) 
 
1.1.2  Prevalence of fungal infections 
The frequency of invasive fungal infections has clearly increased in recent years.  This was 
reported in a study of the epidemiology of sepsis in the United States, where the results 
showed that the annual number of cases of sepsis caused by fungal organisms increased by 
more than two-fold between 1979 and 2000 (Martin et al., 2003).  Data collected from 49 
hospitals over a 7-year period (1995-2002) revealed that Candida species had become the 







Candida and Aspergillus remain the most well-known cause of opportunistic pathogens, with 
an annual incidence of 72 – 290 infections per million people for Candida and 12-34 
infections per million people for Aspergillus (Rees et al., 1998).  Although there have been 
significant advances in antifungal drug development, the available drugs do not meet all the 
requirements of managing infections in the complex patient populations.  The development of 
more antifungal drugs is urgently needed.  
1.1.3  Antifungal resistance to azoles  
The development of resistance of fungal species to therapeutic drugs has become increasingly 
apparent, and is a dominant factor for the concomitant rise in invasive fungal infections.  
Resistance is defined as the inability of an antifungal agent to inhibit the growth of the 
organism at concentrations that are achieved with normal dosing (Pfaller, 2012).  Clinical 
resistance is defined as the inability to eradicate a fungal infection despite the use of 
antifungal agents at normal dosage (Pfaller, 2012). 
The four mechanisms for azole resistance was described by Kanafani (2008); the first is the 
regulation of efflux pumps, which decreases the concentration of the drug at the target site, 
the second is point mutations which alter the target site, the third is over expression of the 
altered site inhibiting binding, and fourth is the development of pathways that bypass the 
disruptive effects of the drugs (Casalinuovo et al., 2004; Kanafani and Perfect, 2008). 
The epidemiology of invasive fungal infections has been reported extensively.  The increase 
in resistance by Candida species to fluconazole, as well as cross resistance to other azoles 







fluconazole resistance from 9% to 14% during the period 2001 to 2007.  A recent study 
conducted by the SENTRY antimicrobial surveillance program in 2008 to 2009, reported on 
the frequency of fungal infections and its associated resistance to azole antifungal agents 
(Pfaller et al., 2010).  These results showed a total of 1239 infections of Candida species with 
the highest resistance rates to fluconazole (16.7%), voriconazole (11%) and posaconazole 
(5%) (Pfellar, 2010). 
The emergence of multidrug resistant species of fungi is a real concern since neither the azole 
nor polyene antifungals are effective against them. The discovery of new and potent 
antifungal azoles is the best way forward in overcoming resistance and developing effective 
therapies. 
1.2  Other Uses of Azoles 
1.2.1 Anti-malarial  
Rodrigues et al. (2011) and Tien Huy et al. (2002) reported known azole mycotics, such as 
ketoconazole and fluconazole, to be active against malaria causing Plasmodium spp. 
Havaldar and Patil (2008), synthesized and screened a series of triazole derivatives for anti-
malarial activity.  Among these derivatives, 3-{4-[4-(4-fluorophenyl)-4H-[1,2,4]-triazol-3-
ylmethoxy]-phenyl}-2-phenyl-3H-quinazolin-4-one (Figure 1-5) was found to be most active 


















Figure 1-5  Structure of 3-{4-[4-(4-fluorophenyl)-4H-[1,2,4]-triazol-3-ylmethoxy]-
phenyl}-2-phenyl-3H-quinazolin-4-one (Havaldar and Patil, 2008) 
 
1.2.2 Anti-tubercular 
Banfi et al. (2006) reported the imidazole derivative (Figure 1-6) as well as miconazole to 
have good anti-tubercular activity when tested against different strains of Mycobacterium 
tuberculosis (MTB) with MICs in the range of 4 to 64 µg mL-1.  Guardiola-Diaz et al. (2001) 
also showed imidazole containing antimycotics, ketoconazole and econazole to inhibit 

















1.2.3 Anticancer  
Compounds having triazole moieties such as vorozole, letrozole and anastrozole are reported 
to be good inhibitors for preventing breast cancer (Clemons et al., 2004).  Demirbas et al. 
(2004) showed the therapeutic activity of the triazole derivative 4-amino-3-phenyl-5-oxo-4,5-
dihydro-[1,2,4]-triazol-1-yl acetic acid 2,4-dichlorobenzylidene hydrazide (Figure 1-7) for 









Figure 1-7 Structure of 4-amino-3-phenyl-5-oxo-4,5-dihydro-[1,2,4]-triazol-1-yl acetic 












1.3  Synthesis of Azoles and its derivatives: 
The general phenylacyl azole moiety (Figure 1-8), seen in many well know azole derivatives, 





Figure 1-8  General structure of the phenylacyl azole moiety 
 
Azole derivatives have been synthesized using a variety of synthetic methodologies.  
Conventional methods using polar aprotic solvents, methods using transition metal salts as 
catalysts and microwave assisted methods have been reported.  
1.3.1 Conventional method 
The conventional synthetic approach reported for phenylacyl azoles is a two-step reaction 
which involves a nucleophilic substitution reaction of the azole with 2-bromoacetophenone in 
the presence of a polar aprotic solvent (Scheme 1-1) since protic solvents would protonate the 
nitrogen of the azoles. 
Güven et al. (2007) reported yields of 60% with the use of dioxane-ether as a solvent whilst 
stirring for 18 hours under ambient conditions.  Mamolo et al. (2004) and Clader et al. (1995) 







solvent.  Although the reaction time used by Mamolo et al. (2004) was considerably longer 
(12 hours) as opposed to the short 1.5 hour reaction time used by Clader et al. (2005).  The 
method proposed by Emami et al. (2008) had proved to be most efficient obtaining yields of 
60%.  This method employed the use of dimethylformamide (DMF), while refluxing at 40-45 






























1.3.1.1  Bromoacetophenones as intermediates for azole substitution 
Various bromination methods of carbonyl compounds have previously been reported, the 
most common being the use of Br2 (Siddiqui and Ahsan, 2010).  Copper-bromide (CuBr2) 
(King and Ostrum, 1964) and N-bromosuccinimide (NBS) (Heasley et al., 1988; Tanemura, 
et al., 2004) have also been used as milder reagents for bromination (Scheme 1-2).  The 
advantage of using CuBr2 and NBS is that they are less toxic and easier to handle.  The use of 
these milder agents did not affect the overall result of the reaction; in fact they were reported 









Scheme 1-2  Bromination of carbonyl compounds   
 
The reactivity of bromoacetophenone is due to the inductive effect of the carbonyl group 
which withdraws electrons toward the oxygen of the carbonyl group resulting in a more 
electrophilic α carbon atom and a weaker C-Br bond (Erian et al., 2003).  The interaction 
between the carbonyl group and the heteroatom is mainly electrostatic and the reaction is 
thought to proceed through an alkoxide intermediate resulting from the nucleophilic azole 







steric requirement of the ketone group as compared to a carbon of the alkyl bromide moiety 
(Erian et al., 2003) (Scheme 1-3).  This is followed by an intramolecular SN2 reaction where 
the azole group is substituted for the weaker bromide base.  The absence of protons to form a 























Scheme 1-3  Mechanism for the SN2 reaction of an azole with bromoacetophenone 








1.3.1.2 Formation of oxime derivatives  
The oxime functional group is incorporated into many medicinal agents, including the 
antifungal agent, Oxiconazole.  Oximes are formed by nucleophillic attack of hydroxylamine 
with the carbonyl carbon of a ketone to form an unstable carbinolamine intermediate (Emami 
et al., 2002).  The carbinolamine intermediate is then broken down to an oxime by an acid 























































1.3.2 Microwave assisted methods  
There are many heterocyclic reactions that can be used for automated medicinal chemistry in 
drug synthesis.  These reactions have traditionally been carried out using solvents and with 
long reaction times.  Microwave synthesis is a technique that has been shown to enhance the 
speed and reproducibility of the reaction (Bougrin et al., 2005).  This was demonstrated by 
Kidwai et al. (2000), who synthesized oxazoles using microwave irradiation by reacting 
reagents on basic alumina in a microwave.  Results showed a dramatic increase in yield and 
















Reaction time: 150 seconds
 
 
Scheme 1-5  The condensation reaction of urea with 1-(4-chlorophenyl)-2-
bromoethanone producing an amino-oxazole, via microwave irradiation (MWI) 








1.3.3 Methods using transition metals  
Limitations such as low yields, long reaction times, difficult work-up and occurrence of side 
reactions warranted the need for better catalysts for the synthesis of azole derivatives.  
Palladium, copper and platinum are the preferred transition metal catalysts used in these 
reactions (Aromi et al., 2011).  Huang et al. (2008), showed the amination of aryl halides 
using imidazole to give higher yields in a shorter reaction time under milder reaction 













Scheme 1-6  Mechanism for the Cross-Coupling of Aryl Halides with imidazole (Huang 
et al., 2008)  
 
The copper (II) acetate forms a four-coordination complex with the imidazole and 1,8-
diazabicycloundec-7-ene (DBU), which then undergoes oxidative addition with the aryl 
halides to form a five-coordination copper complex, which is then reduced to produce the 
































Copper complex intermediate Copper complex intermediate
1-phenyl-1H -imidazole
 
Scheme 1-7   Possible mechanism of N-arylation promoted by copper (II) acetate 








1.4 Aims and objectives: 
Since the azole functional group is present in many antibacterials and antifungals such as 
miconazole, econazole and ketoconazole, it was hypothesised that this functional group 
present in other carbon backbones could also possess antifungal and antibacterial activity.  
Hence we decided to explore the phenylacyl and 2-hydroxyphenylacyl azoles and their oxime 
derivatives. 
The specific aim of the project was to synthesise a small library of phenylacyl and 2-
hydroxyphenylacyl azoles and their oxime derivatives and to assess the synthesized 
compounds for their antimicrobial activity against different strains of fungi and bacteria. 
 Objectives of the study 
1. To synthesize substituted phenylacyl and 2-hydroxyphenylacyl azoles and their oxime 
derivatives in a three step reaction from acetophenone and 2-hydroxyacetophenone. 
2. To investigate and compare the effect that the oxime group and hydroxy substitution 
at the 2ʹ postion has on antifungal activity.  








Chapter 2. Experimental 
2.1 General 
Nuclear magnetic resonance (NMR) spectra were recorded on Bruker AVANCE III 400 MHz 
spectrophotometer.  1H and 13C NMR spectra were recorded at 400 MHz and 100 MHz 
respectively, at 30 °C with chemical shifts (δ) recorded against the internal standard, 
tetramethylsilane (TMS).  Melting points were recorded on an Ernst LeitzWetziar micro-hot 
stage melting point apparatus and are uncorrected.  Thin layer chromatography (TLC) was 
performed using Merck Kieselgel 60 F254 plates.  Column chromatography was carried out 
using silica gel 60.  Infrared (IR) spectra were recorded neat from the Perkin Elmer 
spectrum100 instrument with a universal ATR attachment.  Ultra Violet (UV) spectra were 
obtained on a Varian Cary UV-VIS Spectrophotometer in methanol.  For Gas 
chromatography Mass spectrometry (GCMS) analyses, the samples were analysed on an 
Agilent GC–MSD apparatus equipped with DB-5SIL MS (30 m x 0.25 mm i.d., 0.25 µm film 
thickness) fused-silica capillary column.  Helium (at 2 mL min-1) was used as a carrier gas.  








2.2 Synthetic procedures 
2.2.1 Synthesis of 2-bromo-1(2-hydroxyphenyl) ethanone intermediate.  
Bromine (0.044  mol, 10 mL) was dissolved in chloroform (50.0 mL) and added drop wise to 
a cold solution of substituted acetophenone (0.040 mol, 5 g) in chloroform (50.0 mL).  The 
reaction mixture was stirred for an additional two hours at room temperature.  The solvent 
was removed in vacuo to yield brominated acetophenones 1 (85% yield) and 2 (70% yield). 
 
2-Bromo-1-phenyl ethanone (1);  
C8H7BrO (199.04 g mol
-1);  
85 % yield;  
White crystals;  
           Mp: 47 - 49 °C;  
Rf = 0.7 (Ethyl acetate/Hexane 10:90); UV λmax nm (log ε): 250 (6.40), 210 (6.32); IR νmax 
(cm
-1
): 3058, 3030, 2942, 1679 (C=O), 1595, 1447, 1277, 1193; 
 1
H NMR (400 MHz, 
CDCl3) δ: 7.96 (d, 2H, J = 7.36 Hz, H-4/8), 7.59 (t, 1H, J = 7.44 Hz, H-6), 7.47 (t, 2H, J = 
8.00 Hz, H-5/7), 4.43 (s, 2H, CH2); 
13
C NMR (100 MHz, CDCl3) δ: 191.49 (C-1), 134.16 
(C-3), 129.13 and 129.06 (C4 –C-8), 31.11 (C-2); EIMS m/z (rel.int.): 202 [M+, Br81] (7), 


















2-Bromo-1-(2-hydroxy-phenyl) ethanone (2); 
  C8H7BrO2 (215.04 g mol
-1);  
70% yield;  
White crystals;  
Mp: 50 - 52 °C;  
Rf = 0.7 (Ethyl acetate/Hexane 10:90); UV λmax nm (log ε): 330 (6.56), 257 (6.46), 210 
(6.38); IR νmax (cm
-1
): 3054, 3008, 2950, 1640 (C=O), 1458, 1448, 1221, 1156, 690 (C-Br);  
1
H NMR (400 MHz, CDCl3) δ: 11.70 (s, 1H, OH), 7.72 (dd, 1H, J = 8.08, 1.48 Hz, H-8), 
7.50 (td, 1H, J = 8.60, 1.48 Hz, H-7), 6.99 (dd, 1H, J = 8.50, 0.68 Hz, H-5), 6.91 (td, 1H, J = 
7.16, 0.84 Hz, H-7), 4.42 (S, 2H, CH2); 
13
C NMR (100 MHz, CDCl3) δ: 197.19 (C-1), 
163.37 (C-4), 137.62 and 130.52 (C-6/8), 119.47 (C-5), 119.11 (C-7), 117.22 (C-3), 30.14 
(C-2); EIMS m/z (rel.int.): 214 [M+, Br79 ] (30), 201 (26), 134 (21), 121 (43), 105 (24), 32 
(100). 
2.2.2 Synthesis of 2-hydroxyphenylacyl azoles 
The desired azole (0.015 mol, 1.0 g) was added to a solution of β-bromoketone (1 – 2, 0.005 
mol, 1.0 g) in DMF (5.0 mL).  The reaction mixture was refluxed with stirring at 65 °C for 4-
8 hours; thereafter it was poured into water and extracted with ethyl acetate.  The organic 
phase was concentrated in vacuo and further purified by column chromatography using 
dichloromethane (DCM): methanol (MeOH) (98:2).  The appropriate fractions were 





















































Scheme 2-1   Synthesis of 2-hydroxyphenylacyl azole and its oxime derivatives  
 
2.2.3 Synthesis of oxime derivatives of 2-hydroxyphenylacyl azoles 
A 6.0 mL solution of ethanol and water (1:1) containing the desired phenylacyl azole (0.005 
mol, 1.0 g) (3 – 5, 9 – 11), sodium hydroxide (0.015 mol, 0.6 g) and hydroxylammonium 
chloride (0.015 mol, 1.1 g) was refluxed with stirring for two hours at 100 ⁰C.  The reaction 
mixture was cooled and the resulting precipitate was vacuum filtered, washed with cold water 









2.3 Physical characteristics, UV, IR and NMR data for phenylacyl azoles 
and their oxime derivatives 
 
2-Imidazol-1-yl-1-phenyl ethanone (3)  
C11H10N2O (186.21 g mol
-1
);  
60% yield;  
Yellow crystals;  
Mp: 115 - 117 °C;  
Rf = 0.5 (DCM/MeOH 95:5); UV λmax nm (log ε): 244 (6.26), 208 (6.19); IR νmax (cm
-1
): 
3380, 3133, 2935,1691 (C=O), 1560, 1595 (C=N), 1516, 1226 (CH2 -N), 1058; 
1
H NMR 
(400 MHz, CDCl3) δ: 7.93 (d, 2H, J = 7.80 Hz, H-7/11), 7.63 (t, 1H, J = 7.48 Hz, H-9), 7.50 
(t, 2H, J = 7.92 Hz, H-8/10), 7.48 (s, 1H, H-5), 7.10 (s, 1H, H-4), 6.92 (s, 1H, H-3) 5.37 (s, 
2H, CH2); 
13
C NMR (100 MHz, CDCl3) δ: 191.60 (C-1), 138.15 (C-5), 134.41 (C-9), 134.18 
(C-6), 129.57 (C-4), 129.13 (C-8/10), 127.97(C-7/11), 120.30 (C-3), 52.47(C-2); EIMS m/z 
(rel. int.): 186 [M
+
 ] (15), 105 (100), 77 (61), 51 (18). 
 
2-(5-Methyl-1H-imidazol-1-yl)-1-phenylethanone (4)  
C12H12N2O2, (200.23 g mol
-1);  
59% yield;  
Yellow crystals; 
































Rf = 0.5 (DCM/MeOH 95:5); UV λmax nm (log ε): 244 (6.39), 205 (6.31); IR νmax (cm
-1
): 
3362, 3135, 2939, 1686 (C=O), 1597 (C=N), 1432, 1228 (CH2-N); 
 1
H NMR (400 MHz, 
CDCl3) δ: 7.95 (d, 2H, J = 7.28 Hz, H-8/12), 7.63 (t, 1H, J = 7.44 Hz, H-10), 7.51 (t, 2H, J = 
7.65 Hz, H-9/11), 6.97 (d, 1H, J = 1.28 Hz, H-4), 6.79 (d, 1H, J = 1.20 Hz, H-3), 5.27 (s, 2H, 
CH2), 2.29 (s, 3H, CH3); 
13
C NMR (100 MHz, CDCl3) δ: 191.75 (C1), 145.72 (C-5), 134.58 
(C-10), 134.51 (C-7), 129.35 (C-9/11), 128.19 (C-8/12), 127.68 (C-4), 120.57 (C-3), 52.21 
(C-2), 13.07 (C-6); EIMS m/z (rel. int.): 200 [M+] (23), 105 (100), 95 (7), 77 (42), 51 (12). 
 
1-Phenyl-2-[1,2,4]triazol-1-yl ethanone (5)  
C10H9N3O (187.20 g mol
-1
);  
65% yield;  
Pale yellow crystals;  
Mp: 114 - 116 °C;  
Rf = 0.6 (DCM/MeOH 95:5); UV λmax nm (log ε): 246 (6.36), 206 (6.28); IR νmax (cm
-1
): 
3114, 2993, 2955, 1697 (C=O), 1597 (C=N), 1505, 1346 (C-N, aromatic), 1226 (CH2-N); 
 1
H 
NMR (400 MHz, CDCl3) δ: 8.22 (s, 1H, H-3), 7.98 (s, 1H, H-4), 7.96 (d, 1H,  J = 7.32 Hz 
H-6/10), 7.64 (t, 1H, J = 7.44 Hz, H-8), 7.51 (t, 2H, J = 7.66 Hz, H-7/9), 5.65 (s, 2H, CH2); 
13
C NMR (100 MHz, CDCl3) δ: 190.74 (C-1), 152.10 (C-4), 145.06 (C-3), 134.76 (C-8), 
134.20 (C-5), 129.36 (C-6/10), 128.30 (C-7/9), 55.20 (C-2); EIMS m/z (rel. int.): M+ not 






















2-(1H-Imidazol-1-yl)-1-phenylethaone oxime (6) 
C11H11N3O (201.22 g mol
-1).  
98% yield;  
Pale yellow crystals; 
 Mp: 154 - 164 °C; 
 Rf = 0.5 (DCM/MeOH 95:5); UV λmax nm (log ε): 246 (6.39), 206 (6.31); IR  νmax (cm
-1
): 
3121, 3003, 2817, 2681 (N-OH), 1238 (CH2-N), 1515, 1499, 1471, 1439, 1287, 957, 938, 
924, 913; 
 1
H NMR (400 MHz, DMSO-d6) δ: 12.06 (s, OH), 7.66-7.68 (m, 2H, H-7 /11) 
7.65 (s, 1H, H-5), 7.36-7.38 (m, 3H, H-8/9/10), 7.04 (s, 1H, H-3), 6.81 (s, 1H, H-4), 5.32 (s, 
2H, CH2);  
13
C NMR (100 MHz, DMSO-d6) δ: 151.90 (C-1), 137.58 (C-5), 133.99 (C-6), 
128.33 (C-4), 128.52 (C-8/10), 129.15 (C-9), 126.00 (C-7 & C-11), 119.53 (C-3), 38.94 (C-
2); EIMS m/z (rel. int.): 201 [M+] (77), 103 (65), 91 (23), 81 (100), 77 (57), 69 (45). 
 
2-(2-Methyl-1H-imidazol-1-yl)-1-phenyl ethanone oxime (7) 





 Mp: 170 - 185 °C; 
 Rf = 0.5 (DCM/MeOH 95:5); UV λmax nm (log ε): 240 (6.38), 204 (6.30); IR νmax(cm
-1
): 
2995, 2586 (N-OH), 1497, 1422, 1277 (CH2-N), 974, 731, 692; 
 1
H NMR (400 MHz, 


































(s, 1H, H-3), 6.60 (s, 1H, H-4), 5.22 (s, 2H, CH2), 2.19 (s, 3H, CH3); 
13
C NMR (100 MHz, 
DMSO-d6) δ: 152.82 (C-1), 144.67 (C-5), 134.38 (C-7), 129.62 (C-10), 128.91(C-9/11), 
126.88 (C-8/12), 126.27 (C-4), 120.68 (C-3), 39.60 (C-2), 12.71 (C-3); EIMS m/z (rel. int.): 
215 [M
+
] (92), 198 (26), 103 (70), 95 (100), 77 (53); HRMS [M
+
 + H] 216.1136, calculated 
for C12H14N3O [M
+ + H] 216.1137.  
 
1-phenyl-2-[1,2,4]triazol-1-yl-ethanone oxime (8) 




White crystals;  
Mp: 145 - 155 °C; 
 Rf = 0.6 (DCM/MeOH 95:5); UV λmax nm (log ε): 247 (6.39), 205 (6.31); IR νmax (cm
-1
): 
3415, 3103, 3010, 2824, 2764, 1515, 1473, 1444, 1279, 1136, 927;  1H NMR (400 MHz, 
DMSO-d6) δ: 7.68 (s, 1H, H-3), 7.01 (s, 1H, H-4), 6.81-6.84 (m, 2H, H-6 /10), 6.50-6.52 (m, 
3H, H-7/8/9), 4.65 (s, 2H, CH2);  
13
C NMR (100 MHz, DMSO-d6) δ: 151.12 (C-1), 150.36 
(C-4), 145.02 (C-3), 134.35 (C-5), 129.02 (C-8), 128.40 (C-7/9), 126.25 (C-6 /10), 42.43 (C-























2.4 Physical characteristics, UV, IR and NMR data for 2-
hydroxyphenylacyl azoles and their oxime derivatives 
 
1-(2-Hydroxy-phenyl)-2-imidazol-1-yl ethanone (9)  
C11H10N2O2 (202.21 g mol
-1
); 
  58% yield;  
Pale yellow crystals;  
Mp: 175 - 177 °C;  
Rf = 0.4 (DCM/MeOH 95:5); UV λmax nm (log ε): 325 (6.42), 251(6.30), 215(6.24); IR νmax 
(cm
-1
): 3123, 2934, 2427 (Ph-OH), 1667 (C=O), 1594 (C=N), 1452, 1231 (CH2- N); 
 1
H 
NMR (400 MHz, CDCl3) δ: 7.70 (d, 1H, J = 8.00 Hz, H-11), 7.54 – 7.61 (m, 2H, H-5/9), 
7.16 (s, 1H, H-4), 7.04 (d, 1H, J = 8.40 Hz, H-8), 6.94-6.96 (m, 2H, H-3/10), 5.44 (s, 1H, 
CH2); 
13
C NMR (100 MHz, CDCl3) δ: 196.88 (C-1), 162.82 (C-7), 140.35 (C-5), 137.82 (C-
9), 131.07 (C-4), 128.64 (C-11), 121.31 (C-6), 119.79 (C-10), 119.38 (C-8), 117.49 (C-4), 
52.12 (C-2);  EIMS m/z (rel. int.): 202 [M
+
] (23), 121 (100), 93 (23), 82 (80). 
 
1-(2-Hydroxyphenyl)-2-(5-methyl-1H-imidazol-1-yl)ethanone (10)   
C12H12N2O2, (216.23 g mol
-1); 
 62% yield;  
Yellow crystals;  


































Rf = 0.4 (DCM/MeOH 95:5); UV λmax nm (log ε): 328 (6.52), 250 (6.40), 216 (6.33);          
IR νmax (cm
-1
): 1651 (C=O), 1577 (C=N), 1194  (CH2-N); 
 1
H NMR (400 MHz, CDCl3) δ: 
7.72 (dd, 1H, J = 8.08, 1.4 Hz, H-12), 7.55 (td, 1H, J = 7.41, 1.56 Hz, H-10), 7.04 (d, 1H, J = 
8.52 Hz, H-9), 6.97 (td, 1H, J = 8.04, 0.84 Hz, H-11), 6.99 (d, 1H, J = 1.2 Hz, H-4), 6.80 (d, 
1H, J = 1.32 Hz, H-3), 5.32 (s, 2H, CH2), 2.30 (s, 3H, CH3); 
13
C NMR (100 MHz, CDCl3) δ:  
197.07 (C-1), 162.82 (C-8), 145.88 (C-5), 137.78 (C-10), 128.62 (C-12), 127.88 (C-4), 
120.60 (C-3), 119.74 (C-11), 119.40 (C-9), 117.57 (C-7), 51.51 (C-2), 13.07 (C-6); EIMS 
m/z (rel.int.): 216 [M+] (30), 121 (100), 96 (84), 65 (30). 
1-(2-Hydroxyphenyl)-2-(1H-1,2,4-triazol-1-yl)ethanone (11)   
C10H9N3O2 (203.19 g mol
-1);  
62% yield;  
Pale yellow crystals;  
Mp: 135 - 137 °C;  
Rf = 0.5 (DCM/MeOH 95:5); UV λ Max
nm
 (log ε) 322 (6.50), 251 (6.40), 212 (6.33);         
IR νmax (cm
-1
) 3126, 2924, 1663 (C=O), 1597 (C=N), 1453, 1229 (CH2-N);  
1
H NMR (400 
MHz, CDCl3) δ: 11.41 (s, 1H, OH), 8.21 (s, 1H, H-3), 8.00 (s, 1H, H-4), 7.70 (d, 1H, J = 
7.88 Hz, H-10), 7.54 (t, 1H, J = 8.12 Hz, H-8), 7.02 (d, 1H, J = 8.48 Hz, H-7), 6.96 (t, 1H, J 
= 7.40 Hz, H-9), 5.68 (s, 2H, CH2); 
13
C NMR (100 MHz, CDCl3) δ: 195.77 (C-1), 162.79 
(C-6), 152.29 (C-4), 145.25 (C-3), 137.96 (C-8), 128.80 (C-10), 119.86 (C-9), 119.29 (C-7), 























1-(2-Hydroxyphenyl)-2-(1H-imidazol-1-yl) ethanone oxime (12) 
C11H11N3O2 (217.22 g mol
-1) 
97% yield; 
Pale yellow crystals;  
 Mp: 165 - 177 °C;   
Rf = 0.4 (DCM/MeOH 95:5); UV λmax nm (log ε): 318 (6.34), 258 (6.23), 221 (6.32);         
IR νmax (cm
-1
): 3124, 2577 (N-OH), 1579 (C=N), 1510, 1478, 1281, 1242 (CH2-N), 1068; 
 
1
H NMR (400 MHz, DMSO-d6) δ: 12.06 (s, 1H, OH), 10.58 (s, 1H, OH), 7.60 (s, 1H, H-5), 
7.35 (dd, 1H, J = 7.52 , 1.56 Hz,  H-11), 7.21 (td, 1H,  J = 8.48, 1.48 Hz , H-9), 7.02 (s, 1H, 
H-3), 6.85 (d,  1H, J = 8.28 Hz, H-8), 6.80 (t, 2H, J = 7.96 Hz, H-4/10), 5.30 (s, 2H, CH2);  
13
C NMR (100 MHz, DMSO-d6) δ: 156.27 (C-7), 154.29 (C-1), 137.70 (C-5), 130.44 (C-9), 
128.95 (C-11), 128.07 (C-3), 119.64 (C-4), 119.29 (C-6), 118.98 (C-10), 116.19 (C-8), 40.69 
(C-2);  EIMS m/z (rel. int.): 199 [M+-H2O], 172 (11), 132 (23), 81(90), 32 (100).     
 
1-(2-Hydroxyphenyl)-2-(2-methyl-1H-imidazol-1-yl) ethanone oxime (13) 
  C12H13N3O2 (231.25 g mol
-1
) 
95% yield;  
Cream crystals;  
Mp: 176 - 188 °C; 
 Rf = 0.4 (DCM/MeOH 95:5); UV λmax nm (log ε): 312 (6.49), 259 (6.41), 225 (6.35);        
IR νmax (cm
-1





































1064, 989, 749, 728; 
 1
H NMR (400 MHz, DMSO) δ: 11.72 (s, 1H, OH), 10.15 (s, 1H, OH), 
7.02 -7.07 (m, 2H, H-10/12), 6.71 (d, 1H, J = 8.12 Hz, H-9), 6.69 (d, 1H, J = 0.64 Hz, H-3), 
6.63 (t, 1H, J = 7.24 Hz, H-11), 6.46 (d, 1H, J = 0.60 Hz H-4), 5.08 (s, 2H, CH2), 2.06 (s, 3H, 
CH3);  
13
C NMR (100 MHz, DMSO) δ: 155.75 (C-8), 153.79 (C-1), 143.96 (C-5), 130.26 
(C-10), 129.40 (C-12), 125.99 (C-4), 120.33 (C-7), 119.87 (C-3), 118.90 (C-11), 115.79 (C-
9), 39.48 (C-2), 12.39 (C-6); EIMS m/z (rel.int.): 213 [M+] (100), 133 (80), 132 (78), 105 
(26), 95 (88), 77 (38); HRMS [M+ + H] 232.1081, calculated for C12H14N3O2 (M
+ + H) 
232.1086. 
 
1-(2-Hydroxyphenyl)-2-(1 H- 1,2,4 triazol-1-yl) ethanone oxime (14) 




  Mp: 230 - 241 °C; 
 Rf = 0.5 (DCM/MeOH 95:5); UV λmax nm (log ε): 308 (6.49), 255(6.40), 216 (6.33);         
IR νmax (cm
-1
): 2650.56 (N-OH), 1577.55 (C=N), 1277.60 CH2-N; 
1
H NMR (400 MHz, 
DMSO-d6) δ: 8.44 (s, 2 × H-3), 7.84 (s, H-4), 7.82 (s, H-4), 7.38 (d, J = 2.28 Hz, H-10), 7.32 
(t, J = 7.68 Hz, H-8), 7.30 (d, J = 2.32 Hz, H-10), 7.18 (td, J = 7.12, 0.92 Hz, H-8), 6.80 (t, J 
= 8.64 Hz, 2 × H-9), 6.76 (d, J = 8.72 Hz, 2 × H-7), 5.50 (s, H-2) and 5.48 (s, H-2); 13C NMR 
(100 MHz,  DMSO-d6) δ: 155.93 (C-6), 155.15 (C-6), 153.13 (C-1), 151.88 (C-1), 151.21 























129.30 (C-8), 122.62 (C-5), 119.76 (C-5), 118.89 (C-7), 118.01 (C-7), 115.94 (C-9), 43.58 
(C-2), 43.20 (C-2). EIMS m/z (rel. int.): 200 [M+ -H2O] (64), 82 (68), 55 (100); HRMS 
[M
+










Chapter 3. Results and discussion 
This chapter contains the chemistry involved in synthesising six phenylacyl azoles and their 
oxime derivatives.  A full structural elucidation is given for some of the compounds and the 




The synthesis of 2-azolyl-2-hydroxyphenyl ethanone derivatives involves two steps (Scheme 
3-1).  The first step involves the bromination of acetophenone using Br2 and chloroform to 
form the α-bromoketones 1 – 2 and the second step entails reacting the α-bromoketone with 
an excess of azole in dimethylformamide (DMF) at 65 °C under reflux to produce the 
corresponding  azole derivatives (3 – 5 and 9 – 11).  The ketones were converted into their 
oxime derivatives by reacting them with an excess of HONH2.HCl in ethanol and water at 
100 °C.  
 
The first step of this synthesis involves the use of one equivalent of bromine to displace one 
hydrogen atom.  It is important that only one equivalent of bromine is used as excess bromine 
results in the removal of both hydrogen atoms from the methyl group of acetophenone, and a 
mixture of di-bromoketone and mono-bromoketone is formed.  The use of copper (II) 







than elemental bromine.  The yields obtained with these reagents were however much lower 





































Scheme 3-1  Synthesis of 2-azolyl-2-hydroxyphenyl ethanone and its oxime derivatives  
 
Table 3-1  Yields obtained for α-bromoketones using different brominating agents 






Br2 2 80-90 88-96
a 
CuBr2 6-8 58 100
b 
NBS 12 47 71
c 








The synthetic approach reported for phenylacyl azoles involves nucleophilic substitution of 
the desired azole with an α-bromoketone in the presence of an aprotic solvent.  The use of 
different solvents and reaction times were investigated to determine optimum yields for 
phenylacyl azoles.  Emmai et al., (2008) used DMF in a 4 – 8 hour reaction which produced 
58% yields.  Güven et al. (2007) used dioxane-ether as the solvent for the reaction, which 
took 18 hours at ambient conditions and produced yields of 60%.  Clader et al. (1995) 
reported yields of 70% with THF for the same reaction.  The use of both THF and dioxane 
was also investigated in this work, where the reactions took between 12 – 20 hours at 65 °C 
and produced between 25 – 40 % of the desired product.  The use of DMF had been the most 
efficient, obtaining yields of 60% with reaction times of 4 – 8 hours (Table 3-2).  The azole 
derivatives (3 – 5 and 9 – 11) were obtained as white or yellow crystals, after further 
purification by column chromatography with DCM: MeOH (95:5).  
Table 3-2   Yields obtained for phenylacyl azoles using different solvents 






DMF 4-8 60 58
a 
THF 12-20 25 70
b 
Dioxane-ether 12-20 30-40 60
c 








The ketone group in compounds (3 – 5 and 9 – 11) was converted into their oxime derivatives 
by the addition of excess sodium hydroxide and hydroxyaluminium chloride.  The reaction 
was refluxed at 100 °C for two hours, and yields of greater than 95% were obtained.  The 
high temperature was needed since a mixture of water and ethanol was used as the solvent.  
All the oxime derivatives (6 – 8 and 12 – 14) had precipitated out of solution once the 
reaction was complete.  They were then washed with ethyl acetate and then cold water to 
remove unconverted ketone derivatives.  
 
The yields and melting points of all 14 synthesized compounds are shown in Table 3-3.  The 
melting points of the α-bromoketones was 47 - 49 °C for 1 and 50 - 52 °C for 2.  Upon 
substitution with an azole moiety the melting points had increased and were greater than 
100°C.  The 2-hydroxy substituted compounds had much greater melting points than the 
unsubstituted compounds.  The melting points of the 2-azolyl-2-hydroxyphenyl ethanone 
oxime derivatives showed an increase compared to their corresponding ketone derivatives. 
The oxime derivatives showed a broad melting point range with a difference of up to 15˚C, 















Table 3-3   Melting points and yields for the 14 synthesized compounds 






1 H C H White 85 47 - 49 
2 OH C H White 70 50 - 52 
3 H C Imidazole Yellow  60 115 - 117 
4 H C 2-methylimidazole Yellow  59 134 - 136 
5 H C 1,2,4-triazole Yellow  65 114 - 116 
6 H N-OH Imidazole Yellow   98 154 - 164 
7 H N-OH 2-methylimidazole White  98 170 - 185 
8 H N-OH 1,2,4-triazole White 98 145 - 155 
9 OH C Imidazole Yellow 58 175 - 177 
10 OH C 2-methylimidazole Yellow  62 164 - 166 
11 OH C 1,2,4-triazole Yellow  62 135 - 137 
12 OH N-OH Imidazole Yellow  97 165 - 177 
13 OH N-OH 2-methylimidazole White  95 176 - 188 







R = H, OH











All the synthesised compounds were characterized using 1H and 13C NMR, infrared (IR) and 
ultra violet (UV) spectroscopy and gas-chromatography mass spectrometry (GC-MS). The 
three novel compounds (7, 13 and 14) were also elucidated using 2D – NMR and high 
resolution mass spectroscopy (HRMS).  
3.2.1 Structural elucidation of phenylacyl azoles and their oxime derivatives 
The IR spectrum of 1 showed a carbonyl absorption at 1679 cm-1 indicating the presence of 
the carbonyl group.  The mass spectrum showed molecular ion peaks typical for that of the 
brominated compound with the Br81 and Br79 molecular ion isotopes at m/z 201 and 199 
respectively.  The peak at m/z 91 is typical of the tropylium cation.  The 
1
H NMR spectrum 
showed the aromatic proton resonances at δH 7.96, a doublet assigned to H-4/8, δH 7.47, a 
triplet ascribed to H-5/7 and another triplet at δH 7.59 which is that of H-6.  The coupling 
constants of the three resonances were between 7.36 and 7.56 Hz, characteristic of ortho 
coupling.  The methylene resonance, H-2 appears as a singlet resonance at δH 4.43 and is 
deshielded because of the electronegative bromine atom.  The 13C NMR spectrum shows the 
presence of the carbonyl group resonance at δC 191.49, together with the methylene 
resonance at δC 31.11 and the aromatic resonances at δC 129.13 and 129.06 (C-4 – C-8), and 
δC 134.16 (C-3).  The 
1H and 13C NMR resonances matched those from the literature (Steiner, 








Upon replacing the bromine in 1 with an imidazole ring in 3, the carbonyl peak in the IR 
spectrum showed a slight shift in wavelength from 1979 to 1691 cm-1.  The imidazole 
aromatic bands were observed at 642-682 cm-1 in the IR spectrum.  The structure was also 
verified by the molecular ion peak at m/z 186 in the mass spectrum. There was no change to 
the aromatic resonances in the 1H NMR spectrum as compared to 1, however as expected 
there was a downfield shift in the methylene resonance H-2 from δH 4.43 in 1 to δH 5.37 in 3 
due to the electronegative nitrogen atom of the imidazole group.  The H-3, H-4 and H-5 
proton resonances of the imidazole moiety were present at δH 6.92, δH 7.10 and δH 7.48 
respectively, the H-5 resonance overlapping with the H-8/10 resonance.  The 13C NMR 
spectrum showed changes in the chemical shifts with respect to the aromatic carbon 
resonances and although these are in the same chemical shift region, the C-9, C-8/10, C-7/11 
can be clearly distinguished at δC134.41, 129.13 and 127.97 respectively.  The remaining 
aromatic resonance C-6 appears at δC134.18 and the imidazole carbon resonances appear at 
δC120.30, δC 129.57 and δC 138.15.  The carbonyl resonance is present at δC 191.60 and C-2 
at δC 52.47, much more deshielded than its corresponding resonance in 1 due to being bonded 
to the imidazole ring.  The proton and carbon resonance assignments were made in 
comparison to 7 below, which were elucidated using HSQC and HMBC data. 
 
The IR spectrum of 4 showed a carbonyl stretching band at 1686 cm-1, which was similar to 
compound 3 at 1691 cm-1.  The aromatic stretching bands of the 2-methylimidazole ring was 
observed in the region of 624-688 cm
-1
.  The mass spectrum of 4 showed the molecular ion 







fragment.  In 4 all the aromatic proton and carbon resonances as well as that for methylene 
resonance and the carbonyl resonance had similar chemical shifts and splitting patterns to that 
of 1 and 3.  However in 4, there were only two imidazole proton resonances as opposed to 
three in 3.  The H-5 resonance that overlapped with H-8/10 at δH 7.48 was absent as indicated 
by the resonance only integrating to two protons in 4 as opposed to three in 3.  This occurred 
with a concurrent appearance of an olefinic methyl resonance at δH 2.29 and a corresponding 
methyl carbon resonance at δC 13.07.  This was assigned to the methyl group at C-5 on the 
imidazole ring.   
 
The H-2 methylene proton resonance showed HMBC correlations to the carbon resonances at 
δC 120.57, 145.72 and the carbonyl resonance at δC 191.75.  Since the resonance at δC 120.57 
was protonated, this was attributed to C-3 with a corresponding doublet proton resonance at 
δH 6.79 (J = 1.28 Hz).  It was now able to assign the remaining olefinic resonance at δH 6.97 
to H-4.  The other resonance showing a HMBC correlation to H-2 at δC 145.72 was 
accordingly ascribed to C-5 as this was a non-protonated carbon resonance, which was 
distinguished from the other non-protonated resonance at δC 134.51 because of HMBC 
correlations to H-3 and H-4.  This resonance (δC 134.51) was thus assigned to C-7.  There 
was also a weak HMBC correlation to H-2 which supported this assignment.   
 
The triazole substitution in 5, afforded a slight shift in the carbonyl stretching band in the IR 
spectrum which was observed at 1697 cm-1.  The azole aromatic bands were observed in the 







observed at m/z 187.  The fragmentation pattern was the same as that in compounds 3 and 4, 
showing the phenacyl fragment as the base peak at m/z 105, and the phenyl ring fragment at 
m/z 77. 
 
In the 1H NMR spectrum of 5, most of the resonances were similar to that of 3 with the 
exception of the azole proton resonances and the methylene proton resonance H-2.  The azole 
proton resonances now occurred at δH 8.22 for H-3 and δH 7.98 for H-4.  These assignments 
were made in accordance with the assignments made for 12 using HMBC correlations 
(discussed below).  The methylene resonance was more deshielded being present at δH 5.65 
as opposed to 5.37 in 3.  This could probably be due to hydrogen bonding with the additional 
nitrogen atom in the azole ring.  As expected there were now only two imidazole carbon 
resonances which were much more deshielded at δC 145.06 (C-3) and δC 152.10 (C-4) than 
their corresponding resonances in 3. 
 
The formation of the imidazole oxime derivative 6 was verified by IR and mass spectroscopy.  
The disappearance of the carbonyl stretching band at 1691cm-1 was observed in the IR 
spectrum of 3 and a broad N-OH band at 2681 cm-1 appeared in 6.  This is indicative that 
formation of the oxime had occurred.  The mass spectrum for compound 6 showed the 
molecular ion peak at m/z 201.  The base peak was observed at m/z 81 which correlates to the 








The H-7/11 resonance in 6 appeared as a multiplet at δH 7.66, slightly more shielded than H-
7/11 in 3.  The H-8, H-9 and H-10 resonances overlap as a multiplet at δH 7.36, also slightly 
more shielded than their corresponding resonances in 3.  The H-5 resonance however is more 
deshielded than that in 3, appearing at δH 7.65 in 6.  The methylene resonance H-2 and the H-
3 and H-4 resonances of the imidazole ring did not differ much from 3.  There was also the 
presence of the extra oxime hydroxy resonance at δH 12.06 in the 
1H NMR spectrum further 
indicating that the oxime had formed.  It must be noted however that the 
1
H NMR data was 
acquired in DMSO whereas that for 3 was acquired in CDCl3 and therefore solvent effects 
could also account for the differences in the 1H NMR chemical shifts.  In the 13C NMR 
spectrum, there was only a difference in the oxime carbon, which occurred at δC 151.90 as 
opposed to the carbonyl resonance at δC 191.60 in 3.  This was accompanied by an upfield 
shift of the C-2 carbon, which occurred together with the solvent peak at δC 38.94, 
determined by HSQC correlations.  The 1H and 13C NMR resonances of 6 matched those in 
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Scheme 3-2   Fragmentation pattern of the oxime derivative 6 
 
In the other two oxime compounds with an unsubstituted phenyl ring (7 and 8), a similar 
splitting pattern was observed for the phenyl ring having two multiplets with similar chemical 
shifts.  These occurred at δH 7.33 and δH 7.50 in 7 and δH 6.50 and δH 6.81 in 8.  Similar to 6, 
the H-2 resonance did not shift much for 7; however there was a noticeable difference in 
chemical shift for H-2 in 8 at δH 4.65 as opposed to 5.66 in 5, the carbonyl derivative.  For 
the triazole oxime derivative 8, the H-3 and H-4 resonances were seen to be shifted to δH 7.68 
and 7.01 in comparison to δH 8.22 and 7.97 in 5.  In the 2-methylimidazole oxime derivative 
7, the H-3 and H-4 resonances appeared at δH 6.89 and δH 6.60 compared to δH 6.97 and δH 







by the pi electrons or this could be due to interaction with the solvent since both these 
compounds were also acquired in DMSO.  The 2-methyl resonance did not change much 
from 4 to 7.  
 
In the 13C NMR spectrum of 8, there was the expected shift of the carbonyl resonance from 
δC 190.74 in 5 to δC 151.12 in 8 and a shift of C-2 from δC 55.21 in 5 to δC 42.43 in 8, similar 
to that observed in compound 6.  There was also an additional shift of the C-8 resonance from 
δC 134.76 in 5 to 129.02 in 8.  The same trend was observed in 7 with the oxime carbon 
resonance being present at δC 152.82, C-2 at δC 39.60 and C-10 at δC 129.62. 
 
The IR spectrum for the oxime derivatives 7 and 8 were similar to 6, showing respective 
broad N-OH stretching bands at 2586 and 2764 cm-1.  The mass spectrum for 7 and 8 showed 
the same trend as 6 by the presence of the benzonitrile ion at m/z 103 for 7 and 8, and the 2-
methylimidazole moiety at m/z 95 for 7.  The molecular ion peaks were observed at m/z 215 
for 7 and m/z 202 for 8. 
 
3.2.2 Structural elucidation of 2-hydroxyphenylacyl azoles and their oxime derivatives  
The IR spectrum of 2 showed a carbonyl absorption at 1640 cm-1 which had more single bond 
character compared to 1679 cm-1 in 1.  The mass spectrum showed a molecular ion peak for 
Br79 at m/z 214.  The base peak at m/z 121 indicated a 2-hydroxyphenacyl cation, due to α-







With the 2-hydroxy substituted bromo compound, 2, the splitting patterns of H-5 and H-8 
were each double doublets and occurred at δH 6.99 (J = 8.50; 0.68 Hz) and δH 7.72 (J = 8.08; 
1.48 Hz).  The H-6 and H-7 resonances appeared as two triplets of doublets at δH 7.50 (J = 
8.60 and 1.48 Hz) and δH 6.91 (J = 7.16 and 0.84 Hz).  The H-8 and H-5 resonances as well 
as the H-6 and H-7 resonances were distinguished based on their electronic effects due to the 
hydroxy group at C-4 where the ortho and para proton resonances are more shielded than the 
meta resonances.  The shielding is due to electron donation by resonance to the oxygen of the 
hydroxy group.  The phenolic hydroxyl resonance was also observed at δH 11.70 due to 
hydrogen bonding with the carbonyl group.  The H-2 proton resonance did not change much 
as compared to 1, appearing at δH 4.42 as a singlet resonance.  In the 
13
C NMR spectrum of 2, 
the carbonyl resonance was present at δC 197.19 and the C-2 resonance at δC 30.14.  The six 
aromatic resonances were present at δC 163.37 for (C-4), δC 117.22 (C-3), 119.48 and 119.11 
(C-5 and C-7 and could be interchangeable), δC 130.52 (C-8) and δC137.62 (C-6). 
 
On formation of the imidazole derivative 9, there were no differences in terms of chemical 
shifts with regard to the aromatic protons, H-8 to H-11, however due to overlap with the 
imidazole protons as indicated by the integration of the spectrum, H-3 with H-10 and H-5 
with H-9 the splitting pattern of the H-9 and H-10 proton resonances could not clearly be 
seen and therefore were recorded as multiplets.  The 1H NMR resonances of 9 occurred at δH 
6.95 (m, H-3/10), δH 7.04 (d, J = 8.40, H-8), δH 7.16 (s, H-4), δH 7.54-7.61 (m, H-5/9), δH 







well as the appearance of the imidazole proton resonances in 9 was evidence that the 
imidazole ring had successfully substituted the bromide.  With reference to the 13C NMR 
spectrum of 9, the only resonance that shifted was understandably the C-2 resonance which 
appeared at δC 52.12 because of the imidazole being substituted for the bromide.  All the 
other resonances of the phenyl ring were similar to that of 2.  
 
The IR spectrum of 9 shows the carbonyl stretching band shift from 1640 cm-1 in 2 to 1667 
cm-1 in 9.  The substitution of the imidazole moiety was also validated by the presence of 
imidazole aromatic stretching bands which occurred at 619-657 cm
-1
.  The molecular ion 
peak of 9 was shown at m/z 202.  The two other major peaks in the mass spectrum of 9 were 
the 2-hydroxyphenyacyl cation at m/z 121, a product of α-cleavage, and the imidazole cation 
at m/z 82.  
 
The 2-methylimidazole 10 and the triazole 11 derivatives of the substituted 2-hydroxy 
compounds were subsequently compared to 2 to determine if there were any changes to the 
phenyl ring.  The azole rings were also compared to the corresponding un-substituted 
compounds 4 and 5 to determine if there were changes to the azoles protons in formation of 
the 2-hydroxy derivatives.  The resonances of these two moieties were similar to those they 









The mass spectra of 10 and 11 showed the same fragmentation pattern as 9 with the base 
peak being present at m/z 121 (2-hydroxyphenacyl cation) for both 10 and 11.  The molecular 
ion peak was detected at m/z 216 for 10 and m/z 203 for 11.  The IR spectra were also similar 
to 9.  The carbonyl stretching bands were visible at 1651 cm
-1
 and 1663 cm
-1
 for 10 and 11 
respectively.   
 
The oxime derivatives of the 2-hyrdoxy substituted ketones (12 – 14) were acquired in 
DMSO and the chemical shifts in the 1H and 13C NMR spectra were different to that of the 
other compounds therefore a discussion on these three compounds are given below. 
 
The 1H NMR spectrum of 12 showed the characteristic splitting pattern for the 2-hydroxy 
substituted phenyl ring having a double doublet at δH 7.35 (J = 7.52, 1.56 Hz) for H-11, a 
triplet of doublets at δH 7.20 (J = 8.48, 1.48 Hz) for H-9, a doublet at δH 6.84 (J = 8.28 Hz) 
for H-8 and a triplet at δH 6.80 (J = 7.96 Hz) attributed to H-10.  The H-4 resonance 
overlapped with the triplet at δH 6.80, the H-3 resonance occurred at δH 7.02 and the H-5 
resonance occurred at δH 7.60 as broad singlets.  The C-5 carbon resonance was indicated by 
a HMBC correlation between C-5 and H-3.  The two hydroxy group proton resonances were 
present at δH 12.07 and 10.58.  The H-2 resonance was present at δH 5.31 as a singlet.  The 
corresponding carbon resonances were assigned using the HSQC spectrum and the 
assignments confirmed by HMBC correlations; 2H-2 with C-3, C-5 and C-1; C-7 with H-11, 











C NMR resonances of 12 matched 
those from the literature (Emami, et al., 2008). 
 
For the 2-methylimidazole oxime derivative 13, proton resonances ortho and para to the 
hydroxy group (H-9 and H-11) retained the splitting pattern but were more shielded at δH 
6.71 (d, J = 8.12 Hz) and δH 6.63 (t, J = 7.24 Hz).  The meta protons H-10 and H-12 both 
overlapped at δH 7.02 – δH 7.07 and was recorded as a multiplet.  The C-3 and C-5 carbon 
resonance of the 2-methyimidazole ring was determined by HMBC correlations to H-2, 
which allowed H-3 to be identified by the HSQC spectrum and the remaining H-4 resonance 
was then determined by elimination.  Thus, H-3 occurred at δH 6.69 (d, J = 0.64 Hz) and H-4 
occurred at δH 6.46 (d, J = 0.60 Hz).  The carbon resonances of C-3, C-4 and C-5 occurred at 
δC 119.87, 125.99 and 143.97 respectively. 
 
Compound 14, the oxime derivative of the 2-hydroxyphenyl triazole ketone was synthesised 
as a mixture of E and Z isomers (Figure 3-1).  This was evident by the twin resonances for H-
2, H-4, H-8 and H-10.  The two H-8 and two H-10 resonances were most notably separated 
from each other and upon adding the integration of the resonances, it is evident that the two 
isomers are present in a racemic mixture.  Various attempts at separating the mixture failed 








































Figure 3-1  Structures of geometric E and Z isomers of the oxime derivative (14) 
 
The two H-2 resonances appeared at δH 5.50 and 5.48.  This resonance was used in the 
HMBC spectrum to identify the two C-5 resonances at δC 122.62 and 119.76, the two C-3 
resonances at δC 145.01 and 144.88 and the two C-1 resonances at δC 153.13 and 151.88.  
Using the HSQC spectrum, H-3 was identified at δH 8.44.  The H-3 resonances for both 
isomers overlapped at this resonance.  This H-3 resonance was then used to identify the C-4 
resonances due to a HMBC correlation between H-3 and the two C-4 resonances at δC 151.21 
and 151.10.   
The two C-6 resonances were then identified at δC 155.93 and 155.15 since these resonances 
are in the aromatic C-O region of the spectrum.  Due to electronic effects by the 2-hydroxy 
group, the ortho (2 × H-7) and para (2 × H-9) resonances were identified more upfield at δH 
6.76 (d, J = 8.72 Hz) and δH 6.80 (t, J = 8.64 Hz) respectively to the two meta protons of H-8 
at δH 7.32 (t, J = 7.68 Hz) and δH 7.18 (td, J = 7.12, 0.92 Hz) and H-10 at δH 7.38 (d, J = 2.28 
Hz) and δH 7.30 (d, J = 2.32 Hz).  We recognize that the coupling constant for the H-10 
resonances are rather small (approximately 2.30 Hz) and should be approximately 8.0 Hz, but 







conversion between the E and Z isomers affect the coupling constant of H-10 as this proton is 
in the vicinity of the oxime but could not find any literature on this phenomenon.  There are 
two corresponding carbon resonances for each of C-7 (δC 118.89 and 118.01), C-8 (δC 130.30 
and 129.30) and C-10 (δC 132.69 and 131.55), but only one for C-9 at δC 115.94.  The two C-
9 resonances for each of the isomers may overlap. 
The molecular ion peaks for the 2-hydroxy substituted oxime derivatives (12 – 14) could not 
be detected in the mass spectra, but a M+ - H2O peak was observed in each of the mass 
spectra (m/z 199 for 12; m/z 213 for 13 and m/z 200 for 14).  The fragmentation patterns were 
similar to the corresponding ketones.  The base peak for 12 at m/z 81, was shown to be the 
imidazole moiety which was cleaved at C-1.  The 1,2-dimethyl-1H-imidazole fragment was 
detected at m/z 95 for 13.  The IR spectrum for compounds (12 – 14) all showed the absence 
of the carbonyl peak, indicating the formation of the oxime group. All oxime derivatives 
showed broad stretching at 2577 cm
-1
 for 12, 2463 cm
-1
 for 13 and 2650 cm
-1
 for 14, 
indicative of the N-OH group.  
The UV spectra for all 14 compounds are in the range of 200 – 260 nm.  The π → π* 
transitions of the phenyl ring was detected at 200 – 220 nm in all 14 compounds.  The 2-









Chapter 4. Antifungal and antibacterial activity 
4.1 Introduction 
Antimicrobial susceptibility testing is an essential technique in many different disciplines, 
from pathology through to drug development (Powers, 2004).  These tests are used to 
determine the efficacy of novel antimicrobials against a number of different microbial species 
(Powers, 2004).  
In vitro susceptibility tests for measuring antifungal activity have been available since the 
1950s.  The methods used currently include broth dilution, agar dilution and disc diffusion.  
Each method has its own advantages and disadvantages, including the type of organism that 
may be accurately tested by the method.  Susceptibility testing with antifungal agents 
(especially with azoles) against yeasts is markedly influenced by medium composition, length 
and temperature of incubation, as well as inoculum size (Pfaller, et al., 1990). 
The broth dilution method determines whether a compound has microbicidal or 
microbiostatic action at a particular concentration.  This procedure involves preparing two-
fold dilutions of drugs in a liquid growth medium dispensed in 96 well plates.  The plates are 
then inoculated with a standardized bacterial suspension.  The lowest concentration of the 
drug that prevents microbial growth represents the minimal inhibitory concentration (MIC).  
Currently, the broth dilution method is recommended for testing commercial antifungal drugs 
targeting yeasts using either the National Committee for Clinical Laboratory Standards 







Susceptibility, 2002).  The advantages of the broth dilution procedure include the generation 
of reproducible MICs, and assistance in generating computerized reports if an automated 96 
well plate reader is used (Jorgensen and Ferraro, 2009). 
The disk diffusion susceptibility method is widely used since it is cost effective and simple to 
use.  The test is performed by applying absorbent discs containing various concentrations of 
the drug on agar growth medium inoculated with bacteria.  The diameter of the clear zone 
around the disc is measured at the end of the incubation period and compared with standard 
drugs (Scorzoni, et al., 2007).   One other advantage of the disk diffusion method is that it 
does not require any specialized equipment and the results can be easily interpreted 
(Jorgensen and Ferraro, 2009).  The disadvantage of using this test method is the lack of 
automation of the test; it is also limiting in that not all bacteria and fungi can be accurately 
tested (Jorgensen and Ferraro, 2009). 
The current study was conducted to investigate the antifungal activity of the 12 synthesized 
compounds since azole derivatives are known as potent antifungal agents.  The susceptibility 
testing was evaluated by the broth micro-dilution method in accordance with the standardized 









4.2.1 Microbial strains 
The antimicrobial activities of the synthesized compounds 3 – 14 were investigated against 
several representative pathogenic organisms, yeast (Candida albicans ATCC 90028, Candida 
albicans ATCC 10231, Candida krusei ATCC 6258, and Candida parapsilosis ATCC 
22019), two gram positive bacteria (Staphylococcus aureus ATCC 43300 and Enterococcus 
faecalis ATCC 5129) and three gram negative bacteria (Escherichia coli ATCC 35218, 
Klebsiella pneumoniae ATCC 700603 and Pseudomonas aeruginosa ATCC 27853). 
Fungal test organisms were grown on sabouraud dextrose agar (30 g L-1), and bacterial test 
organisms on Muller-Hinton agar (21 g L-1) at 35-37 °C in a CO2 incubator for 24 hours. 
Organisms were suspended in saline and the turbidity was adjusted to 0.5 McFarland 
standard.  This suspension was further diluted with saline to give a final suspension of 1-5 x 
10
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For susceptibility testing procedures a synthetic medium Roswell Park Memorial Institute 
(RPMI) 1640 medium was used.  This was supplemented with glucose and buffered with 
0.165 M morpholine propane sulfonic acid (MOPS, Sigma-Aldrich) to pH 7.0.  Sabouraud 
dextrose agar (Merck) and Muller-Hinton agar were reconstituted according to the 








(MTS, Promega Corporation, Madison, USA) was prepared by dissolving the MTS salt in 
phosphate buffered saline.  Iodonitrotetrazolium chloride (INT) solution was freshly prepared 
in phosphate buffered saline to a final concentration of 200 µg mL
-1
.  Each microplate well 
was measured after 24 hours of incubation with a 96-well microplate spectrophotometer 
(Mindray MR-96A) set at a wavelength of 490 nm. 
  
4.2.3 Preparation of antimicrobial agents 
Stock solutions (10 µg mL-1) of the synthesized compounds 3-14 and reference drugs, 
Amphotericin B and Neomycin (Sigma Aldrich) were freshly prepared in dimethyl sulfoxide 
(DMSO).  The final concentration of test compounds ranged from 0.0012 to 200 µg mL
-1
 and 
Amphotericin-B ranged from 0.0015 to 100 µg mL-1 and Neomycin from 0.0076 to 500 µg 
mL-1.  All drug dilutions were carried out in 96-well flat bottom microtitre plates; each well 
contained 100 µL of two fold serial dilutions of the drugs tested and were stored at -70 °C 
until the day of testing. 
 
4.2.4 Antifungal susceptibility testing 
Evaluation of the susceptibility of Candida albicans and non- Candida albicans species was 
performed using the broth microdilution method according to the NCCLS reference 
procedure M27-A2.  Yeast strains were grown aerobically overnight at 35 °C on Sabouraud 







turbidity of the supernatants measured spectrophotometrically at 625 nm with an absorbance 
of 0.08-0.1 equivalents to the No. 0.5 Mc Farland standard according to the NCCLS M27-A2 
guidelines.  The working suspension was diluted to 1:20 in RPMI 1640.  The working 
suspension was further diluted with the medium (1:50) to obtain the final test inocula (1.0 - 
1.5 x103 CFU mL-1).  The microtitre plates containing different concentrations of test 
compounds were allowed to thaw and equilibrate to room temperature under aseptic 
conditions.   Aliquots of 100 µL of working inoculum suspensions were dispensed into each 
well and the plates incubated in an aerobic environment at 35 °C for 24 hours.  After 
incubation, 20 µL of MTS salt was added directly to each well and incubated at 37 °C for 4 
hours.  The formation of formazan crystals was quantified by measuring the absorbance at 
490 nm on a 96-well plate reader.  All analyses were performed in triplicate and data are 
reported as the mean ± standard error of the mean of ≤ 5. 
 
4.2.5 Antibacterial susceptibility test: 
Bacterial susceptibility testing was carried out using the micro broth dilution method (Eloff, 
1998; NCCLS M7-A5, 2000; Schwalbe et al., 2007).  The 16 – 18 hour overnight cultures, 
which were incubated at 37 °C, were adjusted to turbidity comparable to a No. 0.5 McFarland 
standard.  The inoculum was adjusted to an absorbance between 0.08-0.1 at 625 nm to yield a 
stock suspension of 0.4 - 0.5 x 108 CFU mL-1 which was diluted one hundred fold to obtain a 
working suspension of 1.0 x 106 CFU mL-1.  Microtitre plates were placed in the laminar flow 







bacterial inoculum were added to the microtiter plates containing appropriately diluted test 
compounds.  Plates were incubated aerobically for 16 - 18 hours at 37 °C.  Following 
incubation, 40 µL of freshly prepared iodonitrotetrazolium chloride solution was added to 
each well and the plate was further incubated for 45 minutes at 37 °C in the dark.  The 
reduced iodonitrotetrazolium formazan (INTF) was measured after extraction with N,N-
dimethyl formamide (DMF).  Persistent growth of bacteria is indicated by a red colour 
change, while no colour change denotes the lack of bacterial growth.  Neomycin was used as 
the control drug in this study.  All analyses were performed in triplicate, and the data is 








4.3 Results and Discussion 
4.3.1 Antifungal activity:  
The in vitro antifungal activities of the synthesized compounds 3 - 14 were investigated 
against four pathogenic strains of Candida species (Table 4-1) using the broth-dilution 
method.  The Minimum Inhibitory Concentration (MIC) values were determined by 
comparison to Amphotericin B (Amp-B) as the reference drug.  The results indicate that 
compounds (9 - 14) with a 2'-hydroxy substitution on the phenyl ring showed better 
antifungal activity than the other test compounds, especially against Candida albicans 
(ATCC 90228) and Candida parapsilosis.   
The 1-(2-hydroxyphenyl)-2-(1H-imidazol-1-yl) ethanone oxime derivative 12 was the most 
potent against C. albicans (ATCC 10231), with a MIC value of 1 µg mL-1, and was 
comparable to that of the reference drug Amphotericin B (MIC 1.2 µg mL-1).  Among the 
compounds tested, 2-(5-methyl-1H-imidazol-1-yl)-1-phenylethanone 4 and 1-(2-
hydroxyphenyl)-2-(5-methyl-1H-imidazol-1-yl)ethanone 10 showed much higher activity 
than the rest of the test compounds against C. albicans (ATCC 90228) with MIC values of 
12.5 and 25 µg mL-1 respectively.   
In general, the compounds containing a triazole or 2-methylimidazole moiety showed better 
activity than its imidazole counterparts.  The oxime derivatives of compounds containing 
imidazole 6 and triazole 8 and 14, showed better antifungal activity against C. albicans 







methylimidazole (7 and 12) had no activity.  C krusei ATCC-5129 was resistant to all the test 
compounds (3 – 14).  
Table 4-1  Minimum Inhibitory Concentration (MIC µg mL
-1
) of test compounds on 
Candida species  









3 - - - 100 
4 12.5 - - - 
5 - - - 200 
6 200 - - - 
7 - - - - 
8 200 - - - 
9 - 12.5 - - 
10 25 - - 12.5 
11 200 - - 12.5 
12 - 1 - - 
13 - 25 - 50 
14 200 - - - 
Amp-B 1.2 1.2 5 1.2 
-: indicates no activity at 200 µg mL-1. Data reported as the mean ± standard error of the mean ≤ 5. 
 
4.3.2 Antibacterial activity  
The antibacterial activity of compounds 3 – 14 were evaluated by the in vitro broth dilution 
assay and the results are presented in Table 4-2.  Two Gram-positive (S. aureus and E. 







strains were employed in the present study and Neomycin (Sigma Aldrich) was used as the 
reference drug.  In general the antibacterial activity was not as good as the antifungal activity 
with moderate activity being exhibited by 6 against S. aureus (MIC of 200 µg mL-1) and K. 
pneumonia (100 µg mL
-1
), 9 against E. coli (MIC of 100 µg mL
-1
) and 5 against P. 
aeruginosa (200 µg mL-1).  Both compounds 6 and 9 contain an imidazole moiety.  All 
compounds were inactive against E. faecalis.  
Compounds containing an oxime group (6 – 8, 12 – 14) as well as 10 containing a 2-
methylimidazole group showed inhibitory activity against K. pneumonia, although all showed 
moderate in vitro antibacterial activity compared to the reference drug Neomycin.  
Table 4-2  Minimum inhibitory concentration of the test compounds (MIC µg mL
-1
) on 













5 - - - - 200 
6 200 - - 100 - 
8 - - - 200 - 
9 - - 100 - - 
10 - - - 200 - 
12 - - - 200 - 
13 - - - 200 - 
Neomycin 10 20 5 10 5 
-: indicates no activity at 200 µg mL-1. Data reported as the mean sd ± ≤5. 









The antifungal and antibacterial results indicate that the synthesized compounds (3 - 14) 
possess moderate antifungal activity and weak antibacterial activity.  These results are in 
agreement with the literature on antimicrobial activity for azole compounds, which show 
them to have antifungal properties.  
In this study, we found the most active compound to be 1-(2-hydroxyphenyl)-2-(1H-
imidazol-1-yl)ethanone oxime 12, at 1 µg mL-1 against C. albicans (ATCC 10231).  In 
general, the 2-hydroxy substituted compounds are shown to be more active against the 
different Candida species, as compared to their unsubstituted counterparts.  The compounds 
containing a triazole or 2-methylimidazole moiety showed higher activity as compared to 
compounds containing an imidazole moiety.   
The antibacterial results also indicated that in general, the 2-hydroxy substituted compounds 
showed better activity.   
These results are only a preliminary screening for the antifungal activity of these compounds.  
Further antifungal testing is needed on non-candida species of yeasts, as well as molds and 
dermatophytes.  From this study it is concluded that 2-hydroxyphenylacyl azole compounds 
have the potential to be antifungal agents and further studies on their structure-activity 









Chapter 5. Conclusion 
The synthesis of the target compounds 1 – 14, were synthesised fairly easily in three steps 
with the only problem being that 14 was not separated into the E and Z isomers.  The yields 
of the reactions were all between 58 and 98%, with almost half of the compounds having 
yields of greater than 90%.  
The use of DMF proved to be the best solvent for the reaction with yields of 60%.  The 
conversion of the ketones to their oxime derivatives was successfully accomplished with 95% 
of the ketone derivatives being converted.  The oxime derivatives that formed were either E 
or Z stereoisomers and could not be separated.  
Further work is needed in order to prepare pure isomers of this compound, or to further purify 
the racemic mixtures.  This could lead to further testing of the purified isomers to investigate 
if the E or Z configuration of the oxime group has an effect on the antifungal activity of the 
compound.  
Three novel compounds, 2-(2-methyl-1H-imidazol-1-yl)-1-phenyl ethanone oxime 7; 1-(2-
hydroxyphenyl)-2-(2-methyl-1H-imidazol-1-yl) ethanone oxime 13; and 1-(2-
hydroxyphenyl)-2-(1H-1,2,4 triazol-1-yl) ethanone oxime 14, were synthesized and their 
structures determined by NMR and confirmed by high resolution mass spectroscopy 
(HRMS). 
Target compounds possessed moderate antifungal activity and weak antibacterial activity 







with a MIC value of 1µg mL-1 against C. albicans.  The triazole and 2-methylimidazole 
derivatives showed better antifungal activity with MIC values in the range of 12.5 to 50 µg 
mL-1.  In general, the 2-hydroxy substituted derivatives showed better antifungal and 
antibacterial activity when compared to their corresponding unsubstituted derivatives.  
The present study shows that 2'-methyl substitution on the azole ring and 2'-hydroxyl 
substitution on the aryl ring lead to enhanced inhibitory activity of the target compounds.  
Further optimization and antifungal screening against a wider range of pathogenic fungi is 
needed to assess the extent of the antifungal activity.  Cytotoxicity screening is also needed to 
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